The primary endpoint.

Amgen Announces Top-Line Results of Phase 3 Throat and Head Cancer Trial Amgen today announced top-line outcomes from a randomized Phase 3 trial evaluating Vectibix seeing that a first-collection treatment in individuals with recurrent and/or metastatic squamous cell mind and neck cancers . The data showed the addition of Vectibix to platinum-based chemotherapy didn’t create a statistically significant improvement in general survival, the primary endpoint, in comparison to chemotherapy alone [median 11.1 months versus 9.0 months, hazard ratio 0.87 ].

from 500 mg to 1000 mg

Amgen announces submission of supplemental New Drug Software to FDA for Kyprolis Amgen today announced the submission of a supplemental New Drug Program to the U.S. Kyprolis has accelerated acceptance in the U currently.S. For the treatment of patients with relapsed multiple myeloma as a monotherapy. The sNDA is founded on data from the global Phase 3 ENDEAVOR trial. Relapsed multiple myeloma individuals treated with Kyprolis and dexamethasone in the ENDEAVOR research lived twice as long without their disease worsening, demonstrating statistically and clinically significant superiority over Velcade . ‘Submission of this brand-new sNDA for Kyprolis can be essential because if approved, it’ll mean more treatment plans for individuals with this serious illness.